Emerging therapies for metabolic diseases-the focus is on diabetes and obesity

Current Opinion in Chemical Biology

Volumn 13, Issue 3, 2009, Pages 332-337

  Hughes, Thomas E ^a  

^a One Cambridge Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; BRAIN DERIVED NEUROTROPHIC FACTOR; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCOSE; LIRAGLUTIDE; MELANOCORTIN 4 RECEPTOR; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

ANXIETY; CLINICAL TRIAL; DEPRESSION; DRUG MECHANISM; ENZYME INHIBITION; FOOD INTAKE; GENE LOCUS; GLYCEMIC CONTROL; HUMAN; HYPOTHALAMUS; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; GLUCOSE; HUMANS; INSULIN-SECRETING CELLS; LIPID METABOLISM; OBESITY; TCF TRANSCRIPTION FACTORS;

EID: 67649877924     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.04.622     Document Type: Review

References (54)

1. Deacon C.F., Carr R.D., and Holst J.J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 13 (2008) 1780
2. Ahrén B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 13 (2008) 593
3. Williams-Herman D., Johnson J., Teng R., Luo E., Davies M.J., Kaufman K.D., Goldstein B.J., and Amatruda J.M. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 25 (2009) 569
4. Rosenstock J., Kim S.W., Baron M.A., Camisasca R.P., Cressier F., Couturier A., and Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9 (2007) 175
5. Mari A., Nielsen L.L., Nanayakkara N., DeFronzo R.A., Ferrannini E., and Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38 (2006) 838
6. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741
7. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Båvenholm P., Efendic S., Eriksson J.W., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869
8. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129
9. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180
10. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457
11. 1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23 (2009) 133
12. Diabetes Genetics Initiative. Genome wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331
13. Zeggini E., Scott L.J., Saxena R., Voight BF., and for the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40 (2008) 638
14. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., and Jackson A.U. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 1341
15. Steinthorsdottir V., Thorleifsson G., Reynisdottir I., Benediktsson R., Jonsdottir T., Walters G.B., Styrkarsdottir U., Gretarsdottir S., Emilsson V., and Ghosh S. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39 (2007) 770
16. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., Boutin P., Vincent D., Belisle A., and Hadjadj S. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445 (2007) 881
17. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., de Bakker P.I.W., Chen H., Roix J.J., Kathiresan S., Hirschhorn J.N., and Daly M.J. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331
18. Lyssenko V., Jonsson A., Almgren P., Pulizzi N., Isomaa B., Tuomi T., Berglund G., Altshuler D., Nilsson P., and Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. New Engl J Med 359 (2008) 2220. The eleven known common single nucleotide polymorphisms affecting diabetes risk were genotyped in over 18 000 subjects, and were related to the development of diabetes and pancreatic beta cell dysfunction over a 23.5 year median follow-up period. While genetic variants were highly significantly associated with risk of developing type 2 diabetes, the combined effects of all genes remained small relative to clinical determinants, particularly body mass index (obesity) and impaired insulin secretion. This is one of the first studies to put genetic and clinical factors into perspective.
19. Meyre D., Delplanque J., Chèvre J.C., Lecoeur C., Lobbens S., Gallina S., Durand E., Vatin V., Degraeve F., Proença C., et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 41 (2009) 157
20. Staiger H., Machicao F., Stefan N., Tschritter O., Thamer C., Kantartzis K., Schäfer S.A., Kirchhoff K., Fritsche A., and Häring HU. Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS ONE 2 (2007) e832
21. Ridderstråle M., and Groop L. Genetic dissection of type 2 diabetes. Mol Cell Endocrinol 297 (2009) 10
22. Orho-Melander M., Melander O., Guiducci C., Perez-Martinez P., Corella D., Roos C., Tewhey R., Rieder M.J., Hall J., Abecasis G., et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57 (2008) 3112
23. Bouatia-Naji N., Bonnefond A., Cavalcanti-Proenca C., Sparso T., Holmkvist J., Marchand M., Delplanque J., Lobbens S., Rocheleau G., Durand E., et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41 (2009) 89
24. Staiger H., Machicao F., Schaefer S.A., Kirchhoff K., Kantartzis K., Guthoff M., Silbernagel G., Stefan N., Haering H.-U., and Fritsche A. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine β-cell function. PLoS ONE 3 (2008) [Epub]
25. Prokopenko, Langenberg C., Florez J.C., Saxena R., Soranzo N., Thorleifsson G., Loos R.J.F., Manning A.K., Jackson A.U., Aulchenko Y., et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 41 (2009) 77
26. Willer C.J., Speliotes E.K., Loos R.J., Li S., Lindgren C.M., Heid I.M., Berndt S.I., Elliott A.L., Jackson A.U., Lamina C., et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 41 (2009) 25
27. Bariohay B., Roux J., Tardivel C., Trouslard J., Jean A., and Lebrun B. BDNF/TrkB signaling is a downstream effector of the brainstem melanocortin system in food intake control. Endocrinol January (2009) [Epub ahead of print], PMID: 19179431
28. Lyssenko V., Lupi R., Marchetti P., Del Guerra S., Orho-Melander M., Almgren P., Sjögren M., Ling C., Eriksson K.F., Lethagen A.L., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117 (2007) 2155. This paper is the first to comprehensively assign functional consequences to a major genetic risk factor for type 2 diabetes. The TCF7L2 risk allele imparts dysfunction in pancreatic islet function that strongly implicates the Wnt signaling pathway and provides theoretical support a range of new drug targets that impact the incretin hormone system and Wnt signaling in pancreatic beta cells.
29. Kim S.-J., Nian C., Widenmaier S., and McIntosh C.H.S. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of β-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 28 (2008) 1644
30. Semple G., Fioravanti B., Pereira G., Calderon I., Uy J., Choi K., Xiong Y., Ren A., Morgan M., Dave V., et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 51 (2008) 5172. This paper outlines the discovery and characterization of one of the first reported GPR119 agonists discovered from the starting point of an inverse agonist high-throughput screening hit. The paper demonstrates improved glucose metabolism in animals treated by oral gavage, establishing efficacy of the chemical class.
31. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7
32. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., Narra K., Hoehn K.L., Knotts T.A., Siesky A., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5 (2007) 161
33. Petersen K.F., and Shulman G.I. Etiology of insulin resistance. Am J Med 119 (2006) S10
34. Vallerie S.N., Furuhashi M., Fucho R., and Hotamisligil G.S. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS 3 (2008) e3151
35. Paton C.M., and Ntambi J.M. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab December (2008) [Epub ahead of print] PMID: 19066317
36. Zhao G., Souers A.J., Voorbach M., Falls H.D., Droz B., Brodjian S., Lau Y.Y., Iyengar R.R., Gao J., Judd A.S., et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 51 (2008) 380. This paper chronicles the optimization of highly potent and orally active DGAT1 inhibitors, and demonstrates their efficacy in rodent models of meal-stimulated plasma lipid excursions, body weight loss in diet-induced obesity, and liver steatosis.
37. Costes S., Vandewalle B., Tourrel-Cuzin C., Broca C., Linck N., Bertrand G., Kerr-Conte J., Portha B., Pattou F., Bockaert J., and Dalle S. Degradation of CREB by the ubiquitin-proteasome pathway contributes to glucotoxicity in β-cells and human pancreatic islets. Diabetes February (2009) [Epub ahead of print] PMID: 19223597
38. Komoroski B., Vachharajani N., Feng Y., Li L., Kornhauser D., Pfister M., and Dapagliflozin. A novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther January (2009) [Epub ahead of print] PMID: 19129749
39. Han S., Hagan D.L., Taylor J.R., Xin L., Meng W., Biller S.A., Wetterau J.R., Washburn W.N., and Whaley J.M. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57 (2008) 1723. This paper describes the pharmacological profiling of dapagliflozin, the presently most advanced SGLT2 inhibitor in clinical trials for type 2 diabetes. The compound was shown to rapidly reduce glycemia and improve glucose utilization in diabetic rat models that normally are difficult to normalize with other anti-diabetic agents, serving as the basis for pharmacological modeling of compounds in this mechanistic class.
40. Rosenstock J., Hollander P., Gadde K.M., Sun X., Strauss R., and Leung A. OBD-202 Study Group: a randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30 (2007) 1480
41. Mondolfi R.N., Jones T.M., Hyre A.D., Raggi P., and Muntner P. Comparison of percent of United States adults weighing ≥300 pounds (136 kilograms) in three time periods and comparison of five atherosclerotic risk factors for those weighing ≥300 pounds to those <300 pounds. Am J Cardiol 100 (2007) 1651
42. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 134 (2008) 405
43. Lavu S, Boss O, Elliott PJ, Lambert PD: Sirtuins-novel therapeutic targets to treat age-associated diseases. Nature Rev Drug Disc 2008, 7:841.
44. Farrell T.M., Haggerty S.P., Overby D.W., Kohn G.P., Richardson W.S., and Fanelli R.D. Clinical application of laparoscopic bariatric surgery: an evidence-based review. Surg Endosc January (2009) [Epub ahead of print] PMID: 19125308
45. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117 (2007) 2362
46. Coleman R.A. How do I fatten thee? Let me count the ways.... Cell Metab 5 (2007) 87
47. Neschen S., Morino K., Hammond L.E., Zhang D., Liu Z.X., Romanelli A.J., Cline G.W., Pongratz R.L., Zhang X.M., Choi C.S., et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2 (2005) 55
48. Yen C.L., Cheong M.L., Grueter C., Zhou P., Moriwaki J., Wong J.S., Hubbard B., Marmor S., and Farese Jr. R.V. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med March (2009) [Epub ahead of print]
49. Cheng D., Iqbal J., Devenny J., Chu C.H., Chen L., Dong J., Seethala R., Keim W.J., Azzara A.V., Lawrence R.M., et al. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 283 (2008) 29802
50. Chen H.C., Smith S.J., Ladha Z., Jensen D.R., Ferreira L.D., Pulawa L.K., McGuire J.G., Pitas R.E., Eckel R.H., and Farese Jr. R.V. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 109 (2002) 1049
51. Miyazaki M., Flowers M.T., Sampath H., Chu K., Otzelberger C., Liu X., and Ntambi J.M. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 6 (2007) 484
52. Dobrzyn A., and Ntambi J.M. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 6 (2005) 169
53. Corbett J.W., and Harwood Jr. J.H. Inhibitors of mammalian acetyl-CoA carboxylase. Recent Pat Cardiovasc Drug Discov 2 (2007) 162
54. Choi C.S., Savage D.B., Abu-Elheiga L., Liu Z.X., Kim S., Kulkarni A., Distefano A., Hwang Y.J., Reznick R.M., Codella R., et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A 104 (2007) 16480